Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYOasmia resolves on a rights issue of approximately SEK 399 millionPREV STORYRoche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone
